INTRODUCTION
Combinations of antimicrobial agents are generally used for one of the following purposes: (i) to increase the bactericidal activity and/or the rate of killing in vivo, (ii) to prevent the emergence of drug resistance, or (iii) to enlarge the antimicrobial spectrum in critically ill patients while awaiting a bacteriologic diagnosis or in patients with polymicrobial infections. Animal models of infection are mainly used to focus on the first two questions. The purpose of this paper is to review the major contributions of animal models in the different aspects of in vivo synergism.
STUDY OF IN VIVO SYNERGISM
The advantage of discriminative models of infection is that, besides the fact that they closely simulate the characteristics of the infection in humans, they provide clear endpoints which allow statistical comparisons among different antibiotic regimens. These endpoints include the number of CFU of bacteria per unit weight of tissue, the frequence of emergence of resistance, the presence or absence of positive blood cultures, death versus survival, and the percentage of observed relapses that occur once treatment is discontinued.
Microbiologists have defined in vitro synergism by various bacteriostatic and bactericidal techniques (34) . In contrast, in vivo synergism is still an undefined concept. The phrase "in vivo synergism" is generally avoided in the literature, and the phrase "enhanced antibacterial activity of the combination in vivo when it is compared with that of either agent alone" has been used instead. In practice, most investigators use statistical methods to evaluate the in vivo effectiveness of combinations, and they call in vivo synergism a statistically significant difference between the activity of a combination and that of the most effective agent alone. However, the fact that a combination of two antibiotics is more effective than either agent alone does not necessarily mean that the combination has synergistic activity in vivo, but it could reflect an additive effect. In contrast, "a bactericidal effect of the drug combination significantly more pronounced than the sum of the bactericidal effect of each agent alone in comparison with the effect in untreated animals" might be a reasonable definition of in vivo synergism, since it implies that the combination induces a bactericidal effect that is more pronounced than expected by the simple addition of the bactericidal effect of each agent alone.
In vitro, it is recommended that at least one of the drugs in a concentration which does not affect the growth curve of the test organism when it is used alone be used. The aim is to use subinhibitory concentrations of at least one agent in * Corresponding author. order to demonstrate the presence of in vitro synergism that would not otherwise be apparent with higher concentrations. However, no recommendation has been made on drug levels for use in the investigation of synergism in vivo. Since the aim of antibiotic combination studies in experimental models of infection is to evaluate in vivo efficacy and to generate data that might be extrapolated to the clinical situation, it therefore seems necessary to use clinically relevant concentrations of and optimal dosing regimens for both agents of the combination.
IN VIVO SYNERGISM AS AN INCREASED BACTERICIDAL ACTIVITY OF THE COMBINATION

Staphylococcal infections. Combination of a 3-lactam agent
with an aminoglycoside consistently showed a beneficial effect in experimental studies. In experimental endocarditis caused by a penicillin-susceptible Staphylococcus aureus strain, a penicillin-gentamicin regimen more rapidly eradicated the organisms from the cardiac vegetations than did either drug alone (53) . When endocarditis was induced in rabbits with a penicillinase-producing strain, an enhanced in vivo bactericidal activity was apparent with nafcillin-gentamicin therapy when compared with the activity of nafcillin alone (54) . For the treatment of experimental osteomyelitis caused by S. aureus, a similar enhanced bactericidal effect was observed between oxacillin and sisomicin compared with the effect of single-drug regimens (45) . These observations paralleled the relative bactericidal rate demonstrated in vitro.
Conflicting results have been reported with combinations that include rifampin. This is mainly because the excellent extravascular and intracellular diffusion of rifampin in vivo does not always overcome the trend toward antagonism that can be observed in vitro in combination with other antibiotics (30, 34) . In experimental endocarditis caused by a penicillin-susceptible S. aureus strain, the combination of penicillin plus rifampin was less effective than penicillin alone (52) . However, more recently, it has been demonstrated that rifampin plus cloxacillin is more effective than cloxacillin alone in experimental endocarditis caused by S. aureus, even though bactericidal titers in serum may suggest antagonism (64) . Also, in experimental staphylococcal osteomyelitis, significantly more bones were sterilized after 4 weeks of therapy when rifampin was combined with an aminoglycoside or cephalothin than when single-drug regimens were used (44) . The triple combination of rifampin, sisomicin, and cephalothin was more effective than any of the dual-agent combinations, with all osteomyelitic lesions sterilized after 2 weeks of therapy (44) .
There is a concern about the use of quinolones in combination with rifampin for the treatment of staphylococcal infections. Microbiological data have shown a possible antagonism between the two agents against staphylococci in vitro (28) . In contrast, pharmacokinetic studies have documented the excellent extravascular and intracellular penetrations of both drugs (6, 30) . In the treatment of experimental osteomyelitis caused by methicillin-resistant S. aureus (MRSA), the ciprofloxacin-rifampin combination has been shown to be an effective regimen that is significantly better than rifampin alone or in combination with vancomycin (24) . Against two MRSA strains with in vitro antagonism between ciprofloxacin and rifampin, antagonism was noted for one strain in the experimental model of endocarditis, but an increased killing by the combination in comparison with that by ciprofloxacin alone was observed for the other strain (28) . This antagonism was not noted in the kidneys and spleens of the infected animals. Thus, as reported for rifampin in combination with penicillin, rifampin combined with quinolones may produce antagonism in vivo, but this is not necessarily predictable by in vitro data (28) .
In the model of endocarditis caused by a MRSA strain, the combination of vancomycin with rifampin was significantly more effective than the single-drug regimens in terms of reducing the mean MRSA vegetation titers, the rate of sterilization of vegetations, and the rate of cure of endocarditis (4). In vitro, the strain was synergistically killed by the combination when it was tested by the time-kill curve method; in contrast, the checkerboard technique indicated that the two drugs were antagonistic against the strain. That study (4) demonstrated the frequent discrepancy observed between in vitro and in vivo results with this combination.
The beneficial effect of the rifampin-vancomycin combination was also demonstrated for the treatment of experimental chronic staphylococcal osteomyelitis (47) . In experimental endocarditis caused by Staphylococcus epidermidis, the addition of gentamicin or rifampin to a glycopeptide antibiotic (either vancomycin or teicoplanin) significantly reduced bacterial titers of vegetations compared with that from the use of a glycopeptide alone (20) . The addition of rifampin alone or gentamicin plus rifampin was significantly more effective than the addition of gentamicin alone. These in vivo results were in contrast to the in vitro time-kill studies, in which rifampin reduced the bactericidal activity of the glycopeptide compound and glycopeptide-gentamicin combinations were the most effective regimens in vitro (20) .
These discrepancies between in vitro and in vivo results paralleled those reported above for the vancomycin-rifampin combination against MRSA in the same model (4) . Thus, it appears likely that the excellent pharmacokinetic properties of rifampin in vivo are able to overcome the trend toward antagonism observed in vitro in combination with glycopeptide antibiotics for therapy of methicillin-resistant staphylococcal infections.
Among the other combinations that have been studied for the treatment of experimental infections caused by MRSA, cefotaxime and fosfomycin were synergistic in the model of experimental meningitis, and that result confirmed in vitro findings (31) . In the endocarditis model, a synergism was observed in vitro and in vivo between pefloxacin and the cell wall-active agent fosfomycin (57) . In the experimental model of endocarditis, the combination of a penicillinase-susceptible ,B-lactam antibiotic (ampicillin or amoxicillin) plus a penicillinase inhibitor (clavulanic acid or sulbactam) was at least as effective as vancomycin and was more effective than penicillinase-resistant P-lactam antibiotics against penicillinase-producing and -nonproducing MRSA isolates (19, 60) . This correlated with a more than 10 times greater penicillin-binding protein 2a affinity of amoxicillin than of methicillin (19) .
Streptococcal infections. Bactericidal synergism occurs in vitro between penicillins and aminoglycosides against virtually all strains of nonenterococcal streptococci (34) . In the model of aortic endocarditis caused of Streptococcus sanguis, 9 days of penicillin therapy was required to sterilize the vegetations. In contrast, if either gentamicin or streptomycin was administered with penicillin, the duration of therapy necessary to achieve vegetation sterility was reduced to 3 to 4 days (52). In the same experimental model, the combination of penicillin and streptomycin was more effective than was penicillin alone in animals infected with penicillintolerant or penicillin-resistant steptococci (62) . Penicillinstreptomycin therapy was less active against the penicillinresistant strain than it was against either penicillin-tolerant or penicillin-susceptible strains. These results suggest that the level of susceptibility of streptococci influences the response to therapy with the penicillin-streptomycin combination. For fully susceptible strains, the addition of an aminoglycoside to penicillin allows a reduction in the duration of therapy, since penicillin alone is already effective; for penicillin-resistant strains, the combination provides higher in vivo efficacy than does penicillin alone.
Enterococcal infections. It is generally recognized that combinations of penicillin and aminoglycoside antibiotics are synergistic in vitro against enterococci, and therefore, they represent optimal therapy for severe infections caused by enterococci without high-level resistance to either compound. This is supposed to represent true in vivo synergism, since neither agent alone is bactericidal against enterococci.
There is a close correlation between in vitro and in vivo results obtained in the enterococcal endocarditis model, with a clear advantage of penicillin-streptomycin over penicillin alone against streptomycin-susceptible strains (25) and penicillin-netilmicin or penicillin-gentamicin over penicillin alone or in combination with streptomycin against streptomycin-resistant strains (11, 33, 63) . Also, the penicillin-gentamicin combination is not effective in the endocarditis model against a 3-lactamase-producing strain of Enterococcus faecium that is highly resistant to penicillin (7) . In the rat model of endocarditis caused by a P-lactamaseproducing strain of Enterococcus faecalis that is highly resistant to penicillin, the combination of penicillin with the P-lactamase inhibitor clavulanic acid has been shown to be an effective regimen that is comparable to the effectiveness of vancomycin, whereas penicillin alone was ineffective (27) .
However, it should be mentioned that this result was obtained with the rat model of endocarditis, which may be a less vigorous test of antibiotic efficacy than the rabbit model because of the smaller vegetations and the lower in vivo inoculum often achieved within cardiac vegetations in the former.
Recent data are available concerning combinations that include glycopeptide antibiotics for therapy of enterococcal infections for strains with lowor high-level resistance to vancomycin. Against a strain of E. faecium with low-level resistance to vancomycin, there was an important increased killing in the endocarditis model with vancomycin or teicoplanin in combination with gentamicin over single-drug regimens (16) . Against another E. faecium strain with highlevel resistance to vancomycin, the triple combination of penicillin, vancomycin, and gentamicin produced a synergistic effect in the same model (9) . However, these results would not be applicable to vancomycin-resistant strains that are also highly resistant to gentamicin (9, 16) .
MINIREVIEW
Infections caused by gram-positive bacilli. In the experimental meningitis model of infection caused by Listeria monocytogenes, the addition of rifampin to penicillin was no more efficacious than penicillin alone; however, the addition of gentamicin to either penicillin or ampicillin was significantly more rapidly bactericidal than was either penicillin or ampicillin alone (55) . The ampicillin-gentamicin combination was the most active regimen in this model.
Infections caused by gram-negative bacilli. Combinations that include a P-lactam agent and an aminoglycoside have frequently produced an increased bactericidal effect in vivo in experimental models of aerobic gram-negative bacillary infections that have generally paralleled an increased rate of killing in vitro (8) . This has included models of endocarditis caused by Escherichia coli (18) , Enterobacter aerogenes (32, 36) , or Pseudomonas aeruginosa (1); pyelonephritis caused by E. coli (21, 22) ; peritonitis (13) ; and other infections caused by P. aeruginosa: septicemia in cytoxan-induced neutropenic rats (38, 56) , osteomyelitis (46) , and pneumonitis in neutropenic animals (29, 50) . In a murine model of peritonitis, combinations of quinolones with ceftriaxone or amikacin tended to be more effective than single-drug treatment against Kiebsiella pneumoniae and Serratia marcescens infections but not against Enterobacter cloacae infections (40, 41, 48) . Against P. aeruginosa, a combination of pefloxacin with ceftazidime or ceftriaxone produced an increased killing, whereas this was not observed with the pefloxacin-amikacin combination. In an infected chamber model in rabbits, ciprofloxacin plus azlocillin was the most effective regimen against six members of the family Enterobactenaceae, was as effective as amikacin plus azlocillin against six P. aeruginosa isolates, and overall, compared favorably with the other combinations by using ciprofloxacin, azlocillin, ceftizoxime, or amikacin (2, 43 ). An important point was the absence of a correlation between in vitro synergism determined by the checkerboard technique and the in vivo outcome. The good efficacy of ciprofloxacin-azlocillin was confirmed in neutropenic mice infected with a lethal challenge of P. aeruginosa (12) . The in vivo data confirmed the in vitro findings, which showed synergism between ciprofloxacin and azlocillin against 30% of P. aeruginosa isolates and no antagonism. In a model of thigh muscle infection caused by E. coli in neutropenic mice, the combination of ciprofloxacin with gentamicin showed an enhanced bactericidal effect when compared with the effect of either agent alone when intermediate ranges of antibiotic doses were used (23) . The sequence of administration of antibiotics did not alter the results that were observed.
The efficacy of P-lactam-p-lactamase inhibitor combinations has been studied in the treatment of experimental gram-negative bacillary endocarditis in rabbits (10, 17) . Against an E. coli strain that produces an SHV-2-like ,B-lactamase, the combination of ceftriaxone and sulbactam was effective only when high doses of each compound were used or when an aminoglycoside was added to the combination (17) . This result could be explained in vitro by the high inoculum effect observed with ceftriaxone. However, for a K pneumoniae strain that produced the TEM-3--13-lactamase, the extremely high MIC (>1,000 ,ug/ml) obtained in vitro with ceftriaxone at a high inoculum explained why synergism with sulbactam could not be achieved in the endocarditis model (10) .
IMPORTANCE OF ANTIBIOTIC DOSING REGIMEN TO ACHIEVE SYNERGISM IN VIVO
If the fact that the combination of a penicillin and an aminoglycoside is synergistic against enterococci without high-level resistance to both compounds seems clear, the best dosing regimen in vivo is still a matter of debate. In the treatment of streptococcal or enterococcal infections in animals, sufficient data are available in the literature to suggest that penicillin levels should be maintained above the MIC throughout the dosing interval, to prevent the loss of efficacy as a result of bacterial regrowth, since no postantibiotic effect has been observed in vivo for penicillin (59) , even in combination with an aminoglycoside (26). In contrast, the optimal dosing regimen for aminoglycosides in combination with penicillin remains controversial. Different investigators reported a concentration-or dose-dependent effect relationship for aminoglycosides combined with penicillin in vitro and ex vivo as well as in the aortic endocarditis model (11, 14) . In contrast, other investigators have shown in vitro and in vivo, using the experimental endocarditis model, that low or high doses of an aminoglycoside are equally effective (25, 39, 63) . An explanation for these discrepancies might be that the dose-effect relationship of an aminoglycoside in vivo describes a sigmoidal curve (35) . Thus, an identical in vivo effect of two different aminoglycoside regimens might correspond to either the lowest or the highest plateau of the sigmoidal dose-response curve. Hence, similar results obtained in vivo with two different doses do not necessarily mean that the dose-effect relationship of an aminoglycoside is not present. Another aspect of an aminoglycoside dosing regimen for the treatment of experimental enterococcal endocarditis is that for the same total daily dose, an increased interval between each aminoglycoside dose is associated with a loss of efficacy (14) . This observation might be explained by the mechanism of penicillin-aminoglycoside synergism against enterococci, which requires the presence of penicillin and an aminoglycoside at the same time so that the cell wall-active antimicrobial agent facilitates the intracellular uptake of the aminoglycoside, which is thought to exert the lethal effect (42) . Opposite findings were reported for the treatment of penicillin-susceptible streptococcal endocarditis in which combinations of penicillin and tobramycin were equally effective whatever the total daily tobramycin dose and dosing regimen tested (51) . This may be related to the fact that, contrary to its effect against enterococcal endocarditis, penicillin alone was bactericidal. For aminoglycoside-,-lactam therapy of experimental infections caused by aerobic gram-negative bacilli, a single daily dosing of an aminoglycoside was at least as effective as conventional dosing regimens (18, 29) . The good efficacy of single daily dosing aminoglycoside strategies could be explained by the concentration-dependent bactericidal activity and the prolonged in vivo postantibiotic effect of aminoglycosides against gram-negative bacilli (35, 58, 59) . These pharmacodynamic characteristics of aminoglycosides result in an in vivo synergism in combination with a 3-lactam antibiotic, as long as the concentration of the ,3-lactam antibiotic remains above the MIC and prevents the bacterial regrowth that follows the postantibiotic effect of the aminoglycoside (18, 29) . This point is particularly important in neutropenic animals (29) , probably because the duration of the postantibiotic effect of an aminoglycoside in vivo is lowered in neutropenic animals in comparison with that in nonneutropenic animals (15) .
Differences in antibiotic dosing regimens may explain VOL. 36, 1992 discrepancies in the literature concerning the presence or absence of in vivo synergism. In the treatment of experimental pneumonia caused by P. aeruginosa, some investigators have shown an increased in vivo efficacy of several 1-lactam-aminoglycoside combinations (50) , as predicted by in vitro synergism testing, whereas other investigators did not show that there is a clear benefit from such combinations (49) . This may be explained in the latter case by less frequent P-lactam dosing, which, in small animals with high renal clearances and with antibiotics with short half-lives, leads to prolonged periods of time with subinhibitory concentrations in vivo, allowing bacterial regrowth. In conclusion, these data demonstrate that optimal antibiotic dosing regimens should be used when in vivo synergism is studied.
IN VIVO SYNERGISM AS THE PREVENTION OF EMERGENCE OF DRUG RESISTANCE Experimental models have defined those in vivo conditions that increase the risk of emergence of drug-resistant bacterial subpopulations. In a murine model of peritonitis, the parameters associated with a higher risk of emergence of resistance during quinolone monotherapy were a high inoculum, the presence of a foreign body, and the type of infecting organism (40, 41) . Despite the use of a high inoculum and the presence of a foreign body, no emergence of quinolone resistance occurred with E. coli or S. aureus; in contrast, the emergence of resistance was frequent with K pneumoniae, S. marcescens, and E. cloacae and was universal with P. aeruginosa. When quinolones were combined with a P-lactam or an aminoglycoside agent, such antimicrobial combinations reduced, but did not fully prevent, the emergence of resistance (41, 48) . j-Lactams were more effective than aminoglycosides in preventing the emergence of resistance to pefloxacin. In animals infected with K pneumoniae, E. cloacae, or S. marcescens, the combination of pefloxacin and ceftriaxone completely prevented the emergence of resistance, whereas the combination of pefloxacin and amikacin reduced the frequency of resistance by more than one-half. Against P. aeruginosa, the protective effect of the combination of a quinolone with a f-lactam agent was incomplete, but it was still more effective than that of the quinolone-amikacin combination in preventing the emergence of drug resistance (40) . Among ,B-lactams, the protective effect of ceftazidime was more pronounced than that of piperacillin, probably because of higher concentrations achieved with ceftazidime in the peritoneal fluid. However, the reduction of resistance observed with the combinations was not always associated with an increased in vivo killing in comparison with that observed with singledrug treatment.
Concerning 3-lactam-aminoglycoside combinations, it
must be emphasized that the development of resistance in vivo may occur despite combination therapy, particularly in severe infections caused by P. aeruginosa, in animals infected with a high inoculum and having a persistent foreign body (5) . The beneficial effect of antibiotic combinations to prevent the emergence of resistance was shown in a model of experimental endocarditis caused by MRSA treated with fosfomycin and pefloxacin alone or in combination (57) . Resistance to fosfomycin arose in 36% of surviving animals with positive vegetation cultures, while resistance to pefloxacin was seen in 4% of animals treated with that drug alone; resistance to either agent was not seen with combination therapy.
The emergence of resistance to rifampin during therapy for severe staphylococcal infection is a well-known problem. In the endocarditis model, the use of vancomycin prevented the in vivo development of resistance to rifampin (4) . In contrast, in a model of experimental osteomyelitis, rifampinresistant staphylococci were detected in all therapeutic failures, regardless of whether rifampin was given alone or in combination with gentamicin, sisomicin, or cephalothin (44) . In a model of severe foreign body infection caused by MRSA, the efficacies of fleroxacin, rifampin, and vancomycin, alone or in combinations, were evaluated in rats (37) . The combination of fleroxacin and rifampin prevented the development of resistance to rifampin, whereas the combination of vancomycin and rifampin did not completely prevent the emergence of resistance to rifampin. This beneficial effect of the fleroxacin-rifampin combination was not due to an increased killing in comparison with the effect of single-drug treatment. The explanation of this result might be that the emergence of resistance to rifampin in vivo is best prevented by a combination which includes another antibiotic with high levels of tissue and intracellular penetration.
IN VIVO SYNERGISM IN POLYMICROBL4L
INFECTIONS The experimental rat model of intraabdominal sepsis is well-suited for the evaluation of therapy of polymicrobial infections (3, 61) . The combination of clindamycin and gentamicin, which covers the spectrum of aerobic and anaerobic pathogens involved in intraabdominal sepsis, is more effective than single-drug therapy in preventing initial death and late abscess formation (61) . Thus, for this indication, the in vivo synergism probably reflects the addition of the activities of two antimicrobial agents which together cover the wide spectrum of bacteria in such polymicrobial infections.
CONCLUSION
Animal models of infection have a unique position between in vitro and clinical studies, allowing important in vivo observations for the study of synergism. However, a clear definition of in vivo synergism is needed. As mentioned above, "a bactericidal effect of the drug combination significantly more pronounced than the sum of the bactericidal effect of each agent alone in comparison with the effect in untreated animals" might be a reasonable definition of in vivo synergism.
Animal models of infection may confirm or contradict in vitro observations concerning antibiotic interactions. When conflicting data are observed, such findings may underscore differences between in vitro and in vivo antibiotic interactions, and they may be based on the pharmacodynamic properties of antibiotic tissue diffusion and bactericidal activity in vivo. As summarized in this review, in vivo synergism involves a variety of different mechanisms, some of which are impossible to analyze by the use of in vitro data, as follows: (i) enhanced bactericidal activity of the combination, as generally demonstrated with ,B-lactam-aminoglycoside combinations; (ii) prevention of the emergence of resistance, as shown for rifampin, fosfomycin and quinolones; (iii) addition of drugs with different antibacterial spectra, as shown in polymicrobial infections; and (iv) "pharmacokinetic synergism," when the increased bactericidal activity of the combination in vivo is due to good tissue distribution rather than in vitro synergism, as shown for rifampin or quinolones. Finally, animal models of infection have helped to define the importance of antibiotic dosing strategies to achieve in vivo synergism. These results may have clinical implications for the therapy of severe infections and in neutropenic patients when optimal bactericidal activity is required.
